October 31, 2023

Flare Therapeutics

Flare Therapeutics to Present New Translational Data in Support of Clinical Candidate FX-909’s Phase 1 Development at SITC 2023 Annual Meeting

October 31, 2023

Asher Bio

Asher Bio Presents Promising New Preclinical Data for Cis-targeted Cancer Immunotherapy AB821 at SITC Annual Meeting

October 31, 2023

Pliant Therapeutics

Pliant Therapeutics Announces Three Presentations at the Annual Meeting of the Society of Immunotherapy of Cancer

October 30, 2023

Rapport Therapeutics

Rapport Therapeutics Appoints Chief Financial Officer

October 19, 2023

Flare Therapeutics

Flare Therapeutics Announces First Patients Dosed in First-in-Human Phase 1 Clinical Study of FX-909 in Advanced Solid Malignancies, Including Urothelial Cancer

Load More

Sign up for weekly portfolio news.